Drug combination for relapsed bone cancers
Part of Bones, joints & muscles, Cancer clinical trials.
This trial tests a combination of three drugs (dinutuximab beta, irinotecan, and rapamycin) for people with bone cancers like osteosarcoma or Ewing sarcoma that have come back or not responded to treatment. The goal is to see if this combination can shrink or slow the tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 6 and 40 years old.
- You must have a type of bone cancer (like osteosarcoma or Ewing sarcoma) that has returned or not responded to treatment.
- You must have had 1 to 3 prior treatments for your cancer.
- You must be able to perform daily activities (performance status of 70% or higher).
- You must not have cancer that has spread to the brain.
- You must have normal heart, kidney, and liver function, as shown by tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of two drugs, cabozantinib and ifosfamide, for sarcomas that have come back or not responded to treatment. The goal is to see if this combination can help shrink or control the cancer.
This study tests a new way of giving a chemotherapy drug called irinotecan (in a liposome form) along with two other chemotherapy drugs (temozolomide and vincristine) versus the standard form of irinotecan with the same two drugs, for people with advanced Ewing's sarcoma. The goal is to see if the new version is safer and works better.
This trial studies a new combination of two drugs, domatinostat and sirolimus, for people with sarcoma or osteosarcoma that hasn't improved after standard treatments. The goal is to see if this combination can help shrink or slow the cancer.
This study tests whether combining two targeted drugs, everolimus and lenvatinib, is better than everolimus alone for people with advanced bone sarcoma. These drugs work by blocking signals that help cancer cells grow and by cutting off the blood supply to tumors.
This trial tests whether adding immunotherapy (a treatment that helps your immune system fight cancer) to chemotherapy can help young people whose bone or soft tissue sarcoma has come back or hasn't responded to previous treatment.
This trial tests a combination of three drugs (liposomal irinotecan, temozolomide, and fluzoparib) for people with Ewing sarcoma that has spread or come back after first treatment. The goal is to see if this combination can help shrink tumors or slow the disease.
Hear when a new Bone Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.